Short Interest in LifeVantage Co. (NASDAQ:LFVN) Decreases By 5.4%

LifeVantage Co. (NASDAQ:LFVN) was the target of a large decline in short interest in December. As of December 31st, there was short interest totalling 191,800 shares, a decline of 5.4% from the December 15th total of 202,800 shares. Based on an average trading volume of 110,600 shares, the short-interest ratio is currently 1.7 days. Approximately 1.9% of the shares of the stock are short sold.

Hedge Funds Weigh In On LifeVantage

Several institutional investors have recently bought and sold shares of LFVN. Barclays PLC raised its stake in shares of LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after acquiring an additional 11,608 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of LifeVantage during the third quarter valued at approximately $638,000. Capital Management Corp VA acquired a new stake in shares of LifeVantage in the third quarter valued at approximately $5,073,000. Renaissance Technologies LLC raised its position in LifeVantage by 2.1% in the 2nd quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock worth $5,490,000 after purchasing an additional 17,300 shares during the last quarter. Finally, Ritholtz Wealth Management lifted its holdings in LifeVantage by 62.0% during the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock worth $346,000 after buying an additional 10,974 shares in the last quarter. Institutional investors own 35.32% of the company’s stock.

LifeVantage Stock Performance

Shares of NASDAQ:LFVN opened at $25.31 on Friday. The company has a market capitalization of $316.88 million, a PE ratio of 79.10 and a beta of 0.82. The company’s fifty day moving average is $16.74 and its 200-day moving average is $12.12. LifeVantage has a 52 week low of $5.22 and a 52 week high of $27.38.

LifeVantage (NASDAQ:LFVN) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 EPS for the quarter, meeting analysts’ consensus estimates of $0.15. The firm had revenue of $47.21 million for the quarter. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%.

LifeVantage Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were issued a dividend of $0.04 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.16 dividend on an annualized basis and a yield of 0.63%. LifeVantage’s dividend payout ratio is 50.00%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on LFVN. Craig Hallum assumed coverage on shares of LifeVantage in a research report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 price target for the company. Lake Street Capital initiated coverage on LifeVantage in a report on Thursday, December 19th. They issued a “buy” rating and a $26.00 target price for the company.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.